MXPA02011524A - Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona. - Google Patents

Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona.

Info

Publication number
MXPA02011524A
MXPA02011524A MXPA02011524A MXPA02011524A MXPA02011524A MX PA02011524 A MXPA02011524 A MX PA02011524A MX PA02011524 A MXPA02011524 A MX PA02011524A MX PA02011524 A MXPA02011524 A MX PA02011524A MX PA02011524 A MXPA02011524 A MX PA02011524A
Authority
MX
Mexico
Prior art keywords
solid body
body forms
novel solid
mesoprogestin
hydroxyiminomethyl
Prior art date
Application number
MXPA02011524A
Other languages
English (en)
Inventor
Gabriele Winter
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA02011524A publication Critical patent/MXPA02011524A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a nuevas formas de cuerpo solido de mesoprogestina 11??-[4E-(hidroxiiminometil)-fenil]-17a-metoxi-metil-17??- metoxi-estra-4,9-dien-3-ona (oxima J 867), de forma particular una forma estable, amorfa altamente cristalina o altamente pura (ansolvato/anhidrato) del compuesto J 867. La invencion tambien se refiere a metodos para producir las nuevas formas de cuerpo solido y al uso de las mismas en composiciones farmaceuticas. Las nuevas formas de cuerpo solido se caracterizan por exhibir un alto grado de estabilidad. Las formas de cuerpo solido de oxima J 867 se pueden usar en particular en el area de control de fertilidad y en la terapia de reemplazo de hormonas.
MXPA02011524A 2000-05-23 2001-05-09 Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona. MXPA02011524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
PCT/EP2001/005237 WO2001090137A2 (de) 2000-05-23 2001-05-09 NEUE FESTKÖRPERFORMEN DES MESOPROGESTINS 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ON

Publications (1)

Publication Number Publication Date
MXPA02011524A true MXPA02011524A (es) 2004-09-10

Family

ID=8168805

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011524A MXPA02011524A (es) 2000-05-23 2001-05-09 Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona.

Country Status (30)

Country Link
US (1) US7799770B2 (es)
EP (3) EP1157996A1 (es)
JP (1) JP2003534350A (es)
KR (1) KR100553292B1 (es)
CN (1) CN100384867C (es)
AT (1) ATE397617T1 (es)
AU (2) AU2001256344B2 (es)
BG (1) BG65968B1 (es)
BR (1) BR0111058A (es)
CA (1) CA2409869C (es)
CZ (1) CZ2003620A3 (es)
DE (1) DE50114012D1 (es)
DK (1) DK1292607T3 (es)
EA (1) EA005623B1 (es)
EC (2) ECSP024358A (es)
ES (1) ES2307613T3 (es)
HR (2) HRP20021032B1 (es)
HU (1) HUP0301956A3 (es)
IL (2) IL152868A0 (es)
ME (1) MEP15608A (es)
MX (1) MXPA02011524A (es)
NO (1) NO327004B1 (es)
NZ (1) NZ522768A (es)
PL (1) PL358789A1 (es)
PT (1) PT1292607E (es)
RS (1) RS50493B (es)
SK (1) SK2922003A3 (es)
UA (1) UA73988C2 (es)
WO (1) WO2001090137A2 (es)
ZA (1) ZA200209322B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2006078731A2 (en) * 2005-01-18 2006-07-27 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
US20090054387A1 (en) 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
ZA200209322B (en) 2005-03-10
ECSP084358A (es) 2008-11-27
EP1862469A2 (de) 2007-12-05
NO20025613D0 (no) 2002-11-22
CA2409869C (en) 2009-02-03
HUP0301956A2 (hu) 2003-09-29
DK1292607T3 (da) 2008-10-13
NZ522768A (en) 2005-03-24
PL358789A1 (en) 2004-08-23
BG65968B1 (bg) 2010-07-30
JP2003534350A (ja) 2003-11-18
EA200201192A1 (ru) 2003-06-26
AU2001256344B8 (en) 2001-12-03
CA2409869A1 (en) 2002-11-20
HUP0301956A3 (en) 2010-03-29
AU5634401A (en) 2001-12-03
ECSP024358A (es) 2003-03-31
MEP15608A (en) 2010-06-10
SK2922003A3 (en) 2003-08-05
US20040006241A1 (en) 2004-01-08
KR100553292B1 (ko) 2006-02-22
ATE397617T1 (de) 2008-06-15
UA73988C2 (en) 2005-10-17
YU88702A (sh) 2006-01-16
IL152868A (en) 2009-08-03
ES2307613T3 (es) 2008-12-01
CN100384867C (zh) 2008-04-30
DE50114012D1 (en) 2008-07-17
HRP20021032B1 (en) 2008-09-30
WO2001090137A2 (de) 2001-11-29
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
EP1157996A1 (de) 2001-11-28
WO2001090137A3 (de) 2002-04-04
IL152868A0 (en) 2003-06-24
PT1292607E (pt) 2008-09-15
EP1292607B1 (de) 2008-06-04
NO20025613L (no) 2002-11-22
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
RS50493B (sr) 2010-03-02
EP1292607A2 (de) 2003-03-19
BR0111058A (pt) 2003-04-15
EA005623B1 (ru) 2005-04-28
HRP20080423A2 (en) 2008-10-31
US7799770B2 (en) 2010-09-21
HRP20021032A2 (en) 2005-02-28
NO327004B1 (no) 2009-04-06
KR20030028742A (ko) 2003-04-10

Similar Documents

Publication Publication Date Title
MXPA02011524A (es) Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona.
MY140674A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
PL367094A1 (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
NZ514711A (en) Compounds useful as anti-inflammatory agents
WO2006135638A3 (en) Tanaproget compositions containing ethinyl estradiol
AU2323897A (en) Cyclopropyl alkanoic acid derivatives
CA2281844A1 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
HUP0103494A2 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
IL111960A0 (en) Morpholines and thiomorpholines, their preparation and pharmaceutical compositions containing them
BG105362A (en) NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
GB0117095D0 (en) "Process for the preparation of pure citalopram"
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
CA2420177A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
CA2429639A1 (en) Stable azithromycin monohydrate
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
BG107407A (en) Novel polymorph v of torasemide
NZ509561A (en) Crystalline forms of osanetant
AU2566101A (en) Compounds and methods for the treatment of pain
RS107004A (en) 9-alpha-substituted estratrienes as selectively active estrogen
WO2002026759A3 (de) 17α-FLUORALKYLSTEROIDE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
HU0102118D0 (en) Process for chloromethylation
HK1044542A1 (en) 11-Beta-aryl-17, 17-spirothiolane-substituted steroids.
PL370479A1 (en) Hexacyclic compounds
HUP0004967A2 (en) New crystalline form of nestorone and process for the preparation thereof
AU2002210537A1 (en) (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration
HC Change of company name or juridical status